Source comparison
Comparison: Tesamorelin vs GLP-1 Agonists vs rhGH — Side Effect Profiles
Injection Site Reactions 26% (mostly Grade 1) 8–12% (transient nodules) 15–20% (lipoatrophy possible) Tesamorelin higher incidence but milder severity; rotation reduces risk Gastrointestinal (nausea, vomiting) 4% (no difference vs placebo) 40–50% during titrat
This comparison does not assign a generated winner or score.
- Injection Site Reactions
- 26% (mostly Grade 1)
- 8–12% (transient nodules)
- 15–20% (lipoatrophy possible)
- Tesamorelin higher incidence but milder severity; rotation reduces risk
- Gastrointestinal (nausea, vomiting)
- 4% (no difference vs placebo)
- 40–50% during titration
- 8–12% (bloating, cramps)
- GLP-1 agonists dominate this category due to gastric emptying mechanism
- Glucose Dysregulation
- HbA1c +0.03% vs placebo
- HbA1c −0.9% vs placebo
- HbA1c +0.3% vs baseline
- GLP-1 improves glucose; rhGH worsens it; tesamorelin neutral
- Peripheral Edema
- 11% (transient, resolved by Week 12)
- 2–4%
- 25–40% (dose-dependent)
- rhGH causes significant fluid retention; tesamorelin mild and self-limiting
- Arthralgia / Joint Pain
- 15% (mild, resolved in 68% by Week 12)
- 6–8%
- 30–45% (carpal tunnel common)
- rhGH causes compression neuropathies; tesamorelin causes transient stiffness
- Bottom Line
- Well-tolerated with minimal metabolic disruption; side effects peak early and resolve
- Effective for weight loss but GI side effects limit adherence in 15–20%
- Potent anabolic effects but high metabolic side effect burden requires monitoring